0001209191-20-045486.txt : 20200806 0001209191-20-045486.hdr.sgml : 20200806 20200806163923 ACCESSION NUMBER: 0001209191-20-045486 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200605 FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YORDON JEFFREY CENTRAL INDEX KEY: 0001189013 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38112 FILM NUMBER: 201082329 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Athenex, Inc. CENTRAL INDEX KEY: 0001300699 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 431985966 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 BUSINESS PHONE: 716-898-8625 MAIL ADDRESS: STREET 1: 1001 MAIN STREET STREET 2: SUITE 600 CITY: BUFFALO STATE: NY ZIP: 14203 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20131223 FORMER COMPANY: FORMER CONFORMED NAME: Kinex Pharmaceuticals LLC DATE OF NAME CHANGE: 20040817 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-05 0 0001300699 Athenex, Inc. ATNX 0001189013 YORDON JEFFREY C/O ATHENEX, INC. 1001 MAIN STREET, SUITE 600 BUFFALO NY 14203 0 1 0 0 See Remarks Common Stock 218926 D Stock Option (Right to Buy) 9.00 2018-06-19 2026-06-19 Common Stock 150000 150000 D Stock Option (Right to Buy) 11.00 2020-06-13 2027-06-13 Common Stock 230000 230000 D Stock Option (Right to Buy) 17.30 2028-03-27 Common Stock 100000 100000 D Stock Option (Right to Buy) 13.17 2029-02-28 Common Stock 100000 100000 D Stock Option (Right to Buy) 12.45 2020-06-05 4 A 0 100000 0.00 A 2030-06-05 Common Stock 100000 100000 D This option vests in four equal annual installments beginning on March 27, 2019. This option vests in four equal annual installments beginning on February 28, 2020. These options were granted contingent on receiving shareholder approval of the Amended and Restated 2017 Omnibus Incentive Plan, which approval was received on June 5, 2020. This option vests in four equal annual installments beginning on June 5, 2021. COO, and President, Athenex Pharmaceutical Division. /s/ Teresa Bair, Attorney-in-Fact 2020-08-06